ES
MARKETS / BALCAO / ALUR
BALCAO · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Allurion Technologies, Inc. ALUR

4 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$15.2M
▼ 52.6% vs FY2024
EPS · FY25
$-3.81
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-188.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 15.2M
Revenue, FY2025 · full 4-year series below
Revenue Net income
0.020.040.060.080.0-0.020222025
0.020.040.060.080.0-0.020222025

The company lost 189 cents on every revenue dollar this year.

Per share
USD -3.81
Diluted EPS, FY2025
EPS
0.40.81.2-3.8120222025
0.40.81.2-3.8120222025

The company pays no cash dividend.

Profitability
—
Return on equity, FY2025
ROE
0.250.50.75120222025
0.250.50.75120222025
Operating margin-198.0%
Net margin-188.8%
Return on assets-118.4%

Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−38.1%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.01B
Shares outstanding, FY2025
0.000.0120222025
0.000.0120222025
Change, 5 years—
Change, 10 years—

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 15.8M
total assets, end of FY2025
Total assetsUSD 15.8M
EquityUSD -77.2M
CashUSD 5.4M
Current ratio0.33×

Equity funds -489% of total assets.

History
4 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
Revenue $B
0.0
0.0
0.1
0.1
Operating income $B
−0.0
−0.1
−0.1
−0.0
EBITDA $B
−0.0
−0.0
−0.1
−0.0
Income tax $B
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.1
−0.0
EPS, diluted $
−3.81
−3.20
−59.38
−37.75
Dividend / sh $
·
·
·
·
Payout %
·
·
·
·
ROE %
·
·
·
·
Shares out B
0.01
0.00
0.00
0.00

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
16 of 16
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed